Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?

Kaya, A.; Tekgunduz, E.; Akpinar, S.; Batgi, H.; Bekdemir, FİLİZ; Kayikci, O.; Namdaroglu, S.; Ulu, B.; Dal, M.; Cakar, M.; Korkmaz, S.; Altuntas, F.

doi:10.1016/j.transproceed.2017.05.007

Is Cytomegalovirus Surveillance Necessary for Patients With Low Reactivation Risk in an Autologous Hematopoietic Cell Transplantation Setting?

Kaya A. H., Tekgunduz E., Akpinar S., Batgi H., Bekdemir F., Kayikci O., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.49, sa.8, ss.1911-1915, 2017 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 49 Sayı: 8
Basım Tarihi: 2017
Doi Numarası: 10.1016/j.transproceed.2017.05.007
Dergi Adı: TRANSPLANTATION PROCEEDINGS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1911-1915
Eskişehir Osmangazi Üniversitesi Adresli: Evet

Özet

Background. In an autologous hematopoietic cell transplantation (AHCT) setting, routine cytomegalovirus (CMV) surveillance is not indicated except in high-risk situations. On the other hand, some studies reported increased CMV reactivation in AHCT setting as a result of incorporation of novel agents into treatment algorithms, such as bortezomib and rituximab. We retrospectively analyzed CMV reactivation and infection rates in patients with no high-risk features, who were treated with AHCT.